Advertisements

Cel-Sci Corporation ($0.001 Par Value) (CVM) Stock Quote

Detailed Quote for Cel-Sci Corporation ($0.001 Par Value) (CVM)
$ 0.1213   0.0212 (+21.18%) Volume: 35.29m 4:02 PM EDT Apr 28, 2017
After Hours:  $ 0.13   0.0087 (+7.17%) Volume: 31.55k 6:53 PM EDT Apr 28, 2017
Today 5d 1m 3m 1y more
Last Price
0.1213
Change $
0.0212
Change %
21.18%
Tick
  
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
0.1115
High
0.1569
Low
0.108
Prev Close
0.1001
Last Trade
04/28/17
Volume
35.29m
52 Wk Hi
0.593999981
52 Wk Low
0.059999998
Market Cap
26.2m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
215,999,614
EPS (TTM)
-0.090000003
PE Ratio
N/A
Exchange
NYSE MKT
News and Media for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Sector News | Topic News
News for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Fri, Apr 28, 2017
11:49 AM CEL-SCI nabs new European patent covering Multikine; shares rally 41% - SeekingAlpha
8:00 AM CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office - Business Wire
Mon, Apr 24, 2017
8:00 AM CEL-SCI Corporation Releases Letter to Shareholders - Business Wire
Wed, Apr 12, 2017
8:30 AM CEL-SCI Scientist Presents at the World Vaccine Congress - Business Wire
Thu, Mar 09, 2017
8:13 AM CEL-SCI commences direct stock offering at $0.10; shares ease 2% premarket - SeekingAlpha
8:00 AM CEL-SCI Announces $1.5 Million Registered Direct Offering - Business Wire
Wed, Mar 08, 2017
8:15 AM Blog Coverage CEL-SCI Provides Update on Late-stage Multikine Head and Neck Cancer Study - Accesswire
Tue, Mar 07, 2017
7:45 AM CEL-SCI clarifies "to do" items to address clinical hold on late-stage Multikine study in head and neck cancer - SeekingAlpha
Mon, Mar 06, 2017
8:00 AM CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine - Business Wire
Mon, Feb 27, 2017
9:40 AM CEL-SCI Announces That the NYSE MKT Approves Plan - Business Wire
Tue, Feb 21, 2017
8:45 AM CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference - Business Wire
Fri, Feb 17, 2017
8:30 AM CEL-SCI Announces $1.0 Million Registered Direct Offering - Business Wire
Thu, Feb 09, 2017
5:36 PM Cel-Sci reports FQ1 results - SeekingAlpha
5:15 PM CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results - Business Wire
Tue, Dec 20, 2016
5:58 PM CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation - Business Wire
Wed, Dec 14, 2016
5:49 PM Cel-Sci reports FY results - SeekingAlpha
5:36 PM CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments - Business Wire
Fri, Dec 09, 2016
6:00 PM CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan - Business Wire
Fri, Dec 02, 2016
7:36 AM CEL-SCI prices equity offering - SeekingAlpha
7:00 AM CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants - Business Wire
More News for CVM >>

Tags for Cel-Sci Corporation ($0.001 Par Value)

Research stocks or mutual funds related to Cel-Sci Corporation ($0.001 Par Value) by keywords or tags. Find companies that have a similar focus to CVM. The keywords below have been associated to CVM by either user submission or electronic means.

biotech research clinical trial enrollment clinical research trial clinical research software laboratory research arthritis causes corporate financial clinical cost disney annual report pharmaceutical study research institutes clinical research consulting Medical Laboratories (8071) annual report asthma clinical trial Biological Products phase iii clinical trials financial report cra clinical research research clinical research technology research phase 3 clinical trials clinical trials manager fda clinical trial medical research immunology reactive arthritis biotechnology research what causes arthritis physician clinical trials Drugs comfort research annual report of company corporate annual report 3m annual report clinical trials recruitment clinical trials conference clinical metabolic research clinical study agreements clinical data Healthcare clinical trial publication clinical research network monitoring clinical research financial statement software clinical research nurse Except Diagnostic Substances (2836) financial statement